Abstract
Antibiotics remain the mainstay of treatment for infectious diseases, but the growing frequency of antibiotic resistance represents a major concern for healthcare worldwide. The use of antibiotics in recurrent infections raises other issues, such as their limitations for treating diverse microorganisms, deleterious effects on the microbiota of the patient and potential adverse effects. In recent years, progress has been made towards the development of novel polybacterial vaccines administered via the mucosal route. These drugs target both the innate and adaptive immune systems, at the actual point of entry of most pathogens. In addition to boosting immune responses, mucosal bacterial vaccines have an intriguing immunomodulatory activity that does not compromise their efficacy against infectious agents. We review here the current clinical evidence concerning the efficacy and safety of these mucosal vaccines for the prevention and treatment of recurrent infection. We also provide an overview completing the landscape of the potential clinical uses of these active biological agents.
Keywords: Immunomodulation, mucosal immune system, mucosal bacterial vaccines, recurrent infections.
Current Drug Targets
Title:Extending the Clinical Horizons of Mucosal Bacterial Vaccines: Current Evidence and Future Prospects
Volume: 15 Issue: 12
Author(s): Silvia Sanchez-Ramon, Rebeca Perez de Diego, Romina Dieli-Crimi and Jose-Luis Subiza
Affiliation:
Keywords: Immunomodulation, mucosal immune system, mucosal bacterial vaccines, recurrent infections.
Abstract: Antibiotics remain the mainstay of treatment for infectious diseases, but the growing frequency of antibiotic resistance represents a major concern for healthcare worldwide. The use of antibiotics in recurrent infections raises other issues, such as their limitations for treating diverse microorganisms, deleterious effects on the microbiota of the patient and potential adverse effects. In recent years, progress has been made towards the development of novel polybacterial vaccines administered via the mucosal route. These drugs target both the innate and adaptive immune systems, at the actual point of entry of most pathogens. In addition to boosting immune responses, mucosal bacterial vaccines have an intriguing immunomodulatory activity that does not compromise their efficacy against infectious agents. We review here the current clinical evidence concerning the efficacy and safety of these mucosal vaccines for the prevention and treatment of recurrent infection. We also provide an overview completing the landscape of the potential clinical uses of these active biological agents.
Export Options
About this article
Cite this article as:
Sanchez-Ramon Silvia, Diego Perez de Rebeca, Dieli-Crimi Romina and Subiza Jose-Luis, Extending the Clinical Horizons of Mucosal Bacterial Vaccines: Current Evidence and Future Prospects, Current Drug Targets 2014; 15 (12) . https://dx.doi.org/10.2174/1389450115666141020160705
DOI https://dx.doi.org/10.2174/1389450115666141020160705 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial (Thematic Issue: New Advances of Drug Design in Cancer Disease Part II)
Current Bioactive Compounds Extra-telomeric Functions of Human Telomerase: Cancer, Mitochondria and Oxidative Stress
Current Pharmaceutical Design Targeted Lipid Nanoparticles for Antisense Oligonucleotide Delivery
Current Pharmaceutical Biotechnology High Expression of Human Leukocyte Antigen-G is Associated with a Poor Prognosis in Patients with PDAC
Current Molecular Medicine The Male Peripubertal Phase as a Developmental Window for Reproductive Toxicology Studies
Current Pharmaceutical Design Gold Nanostructures as Photothermal Therapy Agent for Cancer
Anti-Cancer Agents in Medicinal Chemistry Synthesis and Stereochemistry-Activity Relationship of Chiral Thiourea Derivatives as Potential Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Are Human Tyrosinase and Related Proteins Suitable Targets for Melanoma Therapy?
Current Topics in Medicinal Chemistry Developments of Combretastatin A-4 Derivatives as Anticancer Agents
Current Medicinal Chemistry Specialisation of the Tropomyosin Composition of Actin Filaments Provides New Potential Targets for Chemotherapy
Current Cancer Drug Targets Potential Medications or Compounds Acting on Toll-like Receptors in Cerebral Ischemia
Current Neuropharmacology Electron Spin Resonance as a Powerful Tool for Studying Antioxidants and Radicals
Current Medicinal Chemistry 2´,3´-Dialdehyde of ATP, ADP, and Adenosine Inhibit HIV-1 Reverse Transcriptase and HIV-1 Replication
Current HIV Research Anticancer Activity of New Haloalkyl Camptothecin Esters against Human Cancer Cell Lines and Human Tumor Xenografts Grown in Nude Mice
Anti-Cancer Agents in Medicinal Chemistry PET with Non-Standard Nuclides
Current Topics in Medicinal Chemistry Evaluation of Salivary Melatonin Levels in HIV-positive Patients: A Historical Cohort Study
Reviews on Recent Clinical Trials Use of Anti-Cancer Drugs, Mitocans, to Enhance the Immune Responses against Tumors
Current Pharmaceutical Biotechnology Pharmacoepigenomics: An Interplay of Epigenetic Modulation of Drug Response and Modulation of the Epigenome by Drugs
Current Pharmaceutical Design Peripheral Benzodiazepine Receptor (PBR) New Insight in Cell Proliferation and Cell Differentiation Review
Current Clinical Pharmacology Targeting MAPK Signalling: Prometheus Fire or Pandoras Box?
Current Pharmaceutical Design